Syngene Purchases First US Manufacturing Facility for $36.5M

Image Credit: Syngene

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, and manufacturing organization (CRDMO), acquired its first biologics site in the United States for $36.5 million.¹

Equipped with multiple monoclonal antibody (mAbs) manufacturing lines, the state-of-the-art biologics facility in Baltimore was officially purchased by Syngene USA Inc.—a wholly owned subsidiary of Syngene—from Emergent Manufacturing Operations Baltimore, LLC (which is an Emergent BioSolutions Inc. subsidiary), and will be available for use beginning the second half of the year. The deal is expected to bolster the CRDMO’s biologics footprint in an effort to further assist customers in both the human and animal health sectors; as part of the agreement, Emergent has the right to secure manufacturing capacity from the facility in the future.

As a result of the latest acquisition, Syngene's total single-use bioreactor capacity now increases to 50,000L, providing large molecule discovery, development, and manufacturing services. The Baltimore plant joins four other development and manufacturing facilities located in India and North America, allowing for an extension of services that include clinical and commercial supply; cell line development; and process optimization. The acquisition—as highlighted by Reuters²—shines light on industry efforts in India to decrease dependence on China for materials and instead, growing in other areas of the world.

"With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers,” explained Peter Bains, CEO Designate, Syngene International Ltd. “This investment will enable Syngene to cater to growing client requirements in an expanding market. It will also provide clients, access to collective service capability of multiple geographic sites, scientists and experience."

Regarding its impact on the US market, company officials noted that the facility will stimulate local economic activity by creating jobs, while not only improving domestic biologics manufacturing capabilities, but also helping to maximize supply chain resilience.

"This facility is a significant milestone for Syngene and comes in response to growing client demand in the United States, the fastest-growing biologics market. It strengthens our offering for animal health clients looking for USDA approval for their products,” said Alex Del Priore, the company’s SVP of development & manufacturing services. “Most importantly, it increases the options we can offer our global customers, providing commercial-scale biologics manufacturing capabilities across our global network and will be underpinned by existing key client projects."

References

1. Syngene Acquires its First Manufacturing Facility in the US. PR Newswire. March 10, 2025. Accessed March 13, 2025. https://www.prnewswire.com/news-releases/syngene-acquires-its-first-manufacturing-facility-in-the-us-302397408.html

2. India's Syngene International acquires first US biologics facility for $36.5 mln. Reuters. March 10, 2025. Accessed March 13, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/indias-syngene-international-acquires-first-us-biologics-facility-50-mln-2025-03-10/